Areas reviewed: In vivo tumor models, oncogenes and tumor suppressor genes in vivo, gene target validation, drug efficacy testing, human genetics/genomics, pharmacogenetics, pharmacogenomics, genetic risk, genotype to phenotype, gene therapy testing, and biomarker identification/development.

Ralph Scully, MD, Chair
Beth Israel Deaconess Medical Center
Boston, MA

Amanda E. Toland, PhD, Vice-Chair
The Ohio State University
Columbus, OH

Jonathan R. Brody, PhD
Thomas Jefferson University
Philadelphia, PA

Kevin M. Brown, PhD
National Cancer Institute
Bethesda, MD

Mark Chiang, MD, PhD
University of Michigan
Ann Arbor, MI

Deborah Cornwall, Stakeholder
Marshfield Hills, MA

Thomas Davies, Stakeholder
Bastrop, TX

Michael E. Engel, MD, PhD
Huntsman Cancer Institute/University of Utah
Salt Lake City, UT

Rani E. George, MD, PhD, MRCP
Harvard Medical School
Boston, MA

Scott A. Gerber, PhD
Dartmouth College
Lebanon, NH

Steven R. Grossman, MD, PhD
Virginia Commonwealth University
Richmond, VA

Lata Jayaraman, PhD
Cerulean Pharma
Cambridge, MA

David Kirsch, MD, PhD
Duke University Medical Center
Durham, NC

W. Kimryn Rathmell, MD, PhD
Vanderbilt University
Nashville, TN

Kristy L. Richards, MD, PhD
Joan and Sanford I. Weill Medical College of Cornell University
New York, NY

Alejandro Sweet-Cordero, MD
Stanford University
Stanford, CA

Katheryn A. Wikenheiser-Brokamp, MD, PhD
Children’s Hospital Medical Center
Cincinnati, OH